Close Menu

cell-free DNA

Guardant is alleging that Foundation's advertising of its own products has harmed both Guardant and cancer patients.

Clinicians say they are using blood-based tests for patients who can't be biopsied as a way to get test results sooner, but implementing tests smartly and appropriately remains a challenge.

While Cynvenio will still perform testing in its own lab right now, the firm's CEO said that interested labs could move the technology in house in the future if they desire.

Advanced cancer patients at the VA will now have access to the company's blood-based PlasmaSelect 64 test as well as the CancerSelect 125 tissue test.

Karius has made its assay available to early-access users and is collaborating on several clinical trials to demonstrate its ability to diagnose infection.

New data points to strong predictive ability for a ddPCR-based test of AR copy number, while other companies are pursuing tests that target expression of AR splice variants.

Cirina will operate as a subsidiary of Grail and the combined entity will collaborate with Dennis Lo's lab at the Chinese University of Hong Kong. 

The company's test measures epigenetic alteration of two genes using Qiagen PCR methods, in order to detect signs of recurrence in colorectal cancer patients post-surgery.

The company's total revenues were $1.7 million, including $897,000 in commercial testing revenue. Its test volume was up 38 percent.

Natera said that the new product would further establish the company as a one-stop shop in the reproductive health market from pre-pregnancy through birth. 

Pages